A Phase 1 interventional study of allogenic amniotic fluid mesenchymal stem cell in Knee Osteoarthritis, sponsored by Siriraj Hospital. Enrolling by invitation at 1 site in Thailand. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-26.
Sponsored by Siriraj Hospital · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Osteoarthritis, Knee with a site in Thailand — 7 open to participants now, 9 under way, 2 of them phase 3. Osteoarthritis, Knee · Thailand.
Among the 44 studies in Osteoarthritis, Knee with a site in Thailand, this one is the 39th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1, and was the 39th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →7 of the 44 studies in Osteoarthritis, Knee with a site in Thailand are open now. Recruiting first, the newest first:
Thammasat University Hospital · Sites in Thailand
Ages 40–80
Phramongkutklao College of Medicine and Hospital · Sites in Thailand
Ages 50+
Ministry of Health, Thailand · Sites in Thailand
Ages 18–100 · Healthy volunteers
Thammasat University Hospital · Sites in Thailand
Ages 40–85
Mahidol University · Sites in Thailand
Ages 50–80
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 9
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 97 across the 40 interventional studies, 80 across the 4 observational. Of the 30 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 44 have an industry lead sponsor. The 10 most frequent:
Siriraj Hospital is the lead sponsor of 95 studies on the registry; 32 are open to participants now.
Siriraj Hospital has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoarthritis, Knee with a site in Thailand that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04318041Phase 3TRB ChemedicaEvaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Osteoarthritis, Knee with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life.
Ten patients, aged between 60 and 80 of both genders, who were diagnosed with knee osteoarthritis at Kellgren and Lawrence (KL) score 2-3 were selected based on strict inclusion and exclusion criteria. Each patient was treated with a single intra-articular injection of 20 million cells of amniotic fluid mesenchymal stem cells in AFCC type into an OA knee. After the treatment, they were monitored through clinical assessment and laboratory investigation, including blood chemistry test and Magnetic Resonance Imaging (MRI) of the treated knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: allogenic amniotic fluid mesenchymal stem cell
Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
Incidence of abnormal physical examination
The following examinations will be conducted: general appearance, respiratory, abdomen, nervous system, muscoskeletal system and etc. In case of abnormal conditions, they shall be recorded as an adverse event.
Time frame: Month -3, Day 0, Month 3, 6 and 12
Incidence of abnormal vital sign
The following assessment will be conducted: heart rate, blood pressure and temperature. In case of abnormal results, they shall be record as an adverse event.
Time frame: Month -3, Day 0, Month 3, 6 and 12
Incidence of abnormal laboratory test results
The following lab tests will be conducted: serum chemistry, haematology, liver function test. In case of abnormal results, they shall be recorded as an adverse event.
Time frame: Day 0, Month 3, 6 and 12
Incidence of abnormal ECG parameters
The following assessments will be conducted: 12 lead ECG recordings with long Lead II, and two-dimensional echocardiography (2D ECHO; if needed). In case of abnormal conditions, they shall be recorded as an adverse event
Time frame: Day 0, Month 3, 6 and 12
The type of Adverse event (AE), numbers of AE and proportion of patients with AE.
AE will be monitored and recorded by the investigator throughout the study.
Time frame: Day 0 to 7, 14, 30, Month 2 to 12
Pain score
Change in pain in the affected knee joint in response to treatments using the Visual Analog Score (VAS)
Time frame: Screening (Month -3), Day 0, Month 3, 6, and 12
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Assessment changes of knee complaints by using the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
Time frame: Screening (Month -3), Day 0, Month 3, 6, and 12
Degree of cartilage change
Assessment change of joint narrowing space width using Radiography (X-ray) and Magnetic Resonance Imaging (MRI)
Time frame: Screening (Month -3), Day 0, Month 3, and Month 12
Ran from Aug 2023 to primary completion in Nov 2023, 3 months.
Of 61 phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Siriraj Hospital